Research Paper Volume 13, Issue 9 pp 12479—12492

LncRNA SUMO1P3 acts as a prognostic biomarker and promotes hepatocellular carcinoma growth and metastasis

SUMO1P3 was upregulated in HCC tissues and cell lines and associated with poor survival in HCC patients. (A) qPCR assay was performed to detect SUMO1P3 expression in 103 pairs of HCC tissues and adjacent noncancerous tissues. GAPDH was used as the endogenous control. (B) Association between SUMO1P3 differential expression and TNM stage. The SUMO1P3 expression was normalized to GAPDH. (C) Kaplan–Meier curves and log-rank test for the 5-year survival rate of HCC patients with high (n=51) or low (n=32) expression of SUMO1P3. (D) qPCR analyses of SUMO1P3 expression in HCC cell lines (BEL-7402, MHCC97L, Hep3B, Huh7, MHCC97H, and HepG2) and the normal hepatocyte cell line LO2. GAPDH was used as the endogenous control. All data are represented as the mean ± SD of three replicates. *P

Figure 1. SUMO1P3 was upregulated in HCC tissues and cell lines and associated with poor survival in HCC patients. (A) qPCR assay was performed to detect SUMO1P3 expression in 103 pairs of HCC tissues and adjacent noncancerous tissues. GAPDH was used as the endogenous control. (B) Association between SUMO1P3 differential expression and TNM stage. The SUMO1P3 expression was normalized to GAPDH. (C) Kaplan–Meier curves and log-rank test for the 5-year survival rate of HCC patients with high (n=51) or low (n=32) expression of SUMO1P3. (D) qPCR analyses of SUMO1P3 expression in HCC cell lines (BEL-7402, MHCC97L, Hep3B, Huh7, MHCC97H, and HepG2) and the normal hepatocyte cell line LO2. GAPDH was used as the endogenous control. All data are represented as the mean ± SD of three replicates. *P < 0.05 vs. Non-tumor or I/II or LO2 group; **P < 0.01 vs. LO2 group.